These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 8108121)

  • 1. Mechanism of action of a dominant-negative mutant of c-Jun.
    Brown PH; Chen TK; Birrer MJ
    Oncogene; 1994 Mar; 9(3):791-9. PubMed ID: 8108121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor.
    Kim S; Brown PH; Birrer MJ
    Oncogene; 1996 Mar; 12(5):1043-53. PubMed ID: 8649795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of oncogene-induced transformation by a deletion mutant of c-jun.
    Brown PH; Alani R; Preis LH; Szabo E; Birrer MJ
    Oncogene; 1993 Apr; 8(4):877-86. PubMed ID: 8455942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos.
    Echlin DR; Tae HJ; Mitin N; Taparowsky EJ
    Oncogene; 2000 Mar; 19(14):1752-63. PubMed ID: 10777209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
    Li JJ; Rhim JS; Schlegel R; Vousden KH; Colburn NH
    Oncogene; 1998 May; 16(21):2711-21. PubMed ID: 9652737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Jun DNA-binding is modulated by mutations between the leucines or by direct interaction of fos with the TGACTCA sequence.
    Hirai S; Yaniv M
    New Biol; 1989 Nov; 1(2):181-91. PubMed ID: 2562220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. cFos is critical for MCF-7 breast cancer cell growth.
    Lu C; Shen Q; DuPré E; Kim H; Hilsenbeck S; Brown PH
    Oncogene; 2005 Sep; 24(43):6516-24. PubMed ID: 16027729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. fos-jun Conspiracy: implications for the cell.
    Verma IM; Ransone LJ; Visvader J; Sassone-Corsi P; Lamph WW
    Princess Takamatsu Symp; 1989; 20():119-26. PubMed ID: 2518685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changing fos oncoprotein to a jun-independent DNA binding protein with GCN4 dimerization specificity by swapping "leucine zippers".
    Sellers JW; Struhl K
    Nature; 1989 Sep; 341(6237):74-6. PubMed ID: 2505087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of a dominant negative c-jun mutant in inhibiting activator protein-1 activation.
    Thompson EJ; Gupta A; Stratton MS; Bowden GT
    Mol Carcinog; 2002 Dec; 35(4):157-62. PubMed ID: 12489106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maf and Nrl can bind to AP-1 sites and form heterodimers with Fos and Jun.
    Kerppola TK; Curran T
    Oncogene; 1994 Mar; 9(3):675-84. PubMed ID: 8108109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AP-1 transrepressing retinoic acid does not deplete coactivators or AP-1 monomers but may target specific Jun or Fos containing dimers.
    Suzukawa K; Colburn NH
    Oncogene; 2002 Mar; 21(14):2181-90. PubMed ID: 11948401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies.
    Brown PH; Kim SH; Wise SC; Sabichi AL; Birrer MJ
    Cell Growth Differ; 1996 Aug; 7(8):1013-21. PubMed ID: 8853897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of dimerization and DNA binding functions in Fos and Jun by domain-swapping: involvement of residues outside the leucine zipper/basic region.
    Cohen DR; Curran T
    Oncogene; 1990 Jun; 5(6):929-39. PubMed ID: 2113670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of c-Fos/c-Jun AP-1 dimer activity by sumoylation.
    Bossis G; Malnou CE; Farras R; Andermarcher E; Hipskind R; Rodriguez M; Schmidt D; Muller S; Jariel-Encontre I; Piechaczyk M
    Mol Cell Biol; 2005 Aug; 25(16):6964-79. PubMed ID: 16055710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transformation by Jun: requirement for leucine zipper, basic region and transactivation domain and enhancement by Fos.
    Morgan IM; Ransone LJ; Bos TJ; Verma IM; Vogt PK
    Oncogene; 1992 Jun; 7(6):1119-25. PubMed ID: 1594243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opposing functions of ATF2 and Fos-like transcription factors in c-Jun-mediated myogenin expression and terminal differentiation of avian myoblasts.
    Daury L; Busson M; Tourkine N; Casas F; Cassar-Malek I; Wrutniak-Cabello C; Castellazzi M; Cabello G
    Oncogene; 2001 Nov; 20(55):7998-8008. PubMed ID: 11753683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 respone element (IRE).
    Schuringa JJ; Timmer H; Luttickhuizen D; Vellenga E; Kruijer W
    Cytokine; 2001 Apr; 14(2):78-87. PubMed ID: 11356008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-range electrostatic interactions influence the orientation of Fos-Jun binding at AP-1 sites.
    Ramirez-Carrozzi VR; Kerppola TK
    J Mol Biol; 2001 Jan; 305(3):411-27. PubMed ID: 11152600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transactivation activity of Maf nuclear oncoprotein is modulated by Jun, Fos and small Maf proteins.
    Kataoka K; Noda M; Nishizawa M
    Oncogene; 1996 Jan; 12(1):53-62. PubMed ID: 8552399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.